- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06686615
원발성 고콜레스테롤혈증 또는 혼합형 이상지질혈증 환자에서 에제티미브와 로수바스타틴 또는 아토르바스타틴을 병용한 Bempedoic Acid에 대한 연구 (TRICONOS)
원발성 고콜레스테롤혈증 또는 혼합형 이상지질혈증 환자에서 에제티미브 및 로수바스타틴 또는 아토르바스타틴과 병용한 Bempedoic Acid의 효과 및 안전성: 관찰 연구
Data on the real-world use and effectiveness and safety of bempedoic acid combined with both a statin and ezetimibe in clinical practice is limited. There is an increased focus on using combination therapy to lower LDL-C.
연구 개요
상태
상세 설명
The aim of the current study is to evaluate the effectiveness and safety of bempedoic acid combined with ezetimibe and either atorvastatin or rosuvastatin (hereafter defined as triple therapy) in a real-world clinical setting. No drug will be administered during this observational study.
The primary objective of the study is to evaluate the effectiveness of the triple therapy in terms of LDL-C reduction at 8 weeks.
The secondary objectives will include the following:
- Goal attainment at 8 weeks and 1 year after start of triple therapy
- Effectiveness of triple therapy in terms of LDL-C reduction at 1 year
- Effectiveness of adding bempedoic acid to statin and ezetimbe at 8 weeks and 1 year
- Effectiveness of adding bempedoic acid/ezetimibe FDC to statin in terms of LDL-C reduction at 8 weeks and 1 year
- Changes in laboratory values at 8 weeks and 1 year after start of triple therapy
- Adherence to triple therapy treatment
- Collection and recording of all adverse events occurred since initiation of triple therapy
- MACE-3 and MACE-4 (consisting of non-fatal MI, non-fatal stroke, CV-death, and coronary revascularization (for MACE-4 only)) during the year of follow-up
- Treatment changes at LMT initiation and at triple therapy initiation
- Treatment pathway from triple therapy initiation to 1-year after start of triple therapy
연구 유형
등록 (추정된)
연락처 및 위치
연구 장소
-
-
-
Aachen, 독일, 52062
- Praxis für Kardiologie Aachen
-
Ahaus, 독일, 48683
- Klinikum Ahaus
-
Alsfed, 독일, 36304
- Praxis W. Almohamed
-
Bad Homburg, 독일, 61348
- Zentrum für klinische Studien Bad Homburg
-
Berlin, 독일, 12627
- Dialysezentrum Hellersdorf Mitte
-
Berlin, 독일, 13353
- Lipidambulanz Charite Campus Virchow
-
Burg, 독일, 03096
- MEDICLIN Reha-Zentrum Spreewald
-
Chemnitz, 독일, 09116
- Kardiologische Gemeinschaftspraxis Flemmingstr.
-
Detmold, 독일, 32756
- Klinik Detmold
-
Dresden, 독일, 01159
- Praxis Dr. Methfessel
-
Dresden, 독일, 01796
- Cardiologicum Dresden
-
Goslar, 독일, 38640
- Herz- und Gefäßmedizin Goslar
-
Greiz, 독일, 07973
- Praxis
-
Gräfenhainichen, 독일, 06773
- ndgl.; viele Kombinationstherapien
-
Hamburg, 독일, 22459
- Kardiologie am Tibarg
-
Hasselt, 독일, 3500
- Jessa Ziekenhuis
-
Heidelberg, 독일, 69115
- HPK Heidelberger Praxisklinik
-
Heidelberg, 독일, 69120
- Uni-Klinik Heidelberg
-
Kaiserslautern, 독일, 67655
- Kardiopraxis
-
Koblenz, 독일, 56073
- GK Mittelrhein
-
Konstanz, 독일, 78464
- Klinikum Konstanz
-
Leipzig, 독일, 04103
- Universitätsklinikum Leipzig
-
Lichtenstein, 독일, 09350
- DRK Krankenhaus Lichtenstein Gemeinnützige GmbH
-
Ludwigsburg, 독일, 71634
- Cardio Centrum Ludwigsburg
-
Mainz, 독일, 55122
- Kardiopraxis
-
Markkleeberg, 독일, 04416
- Kardiologische Praxis Markkleeberg
-
Moers, 독일, 47441
- Kardiologie Gem. Praxis Dres Reiff/Linse/Haj-Yehia/Specking
-
Mühldorf A. Inn, 독일, 84453
- Praxis Dr. Norbert Schön
-
Papenburg, 독일, 26871
- Kardiologische Gemeinschaftspraxis Papenburg
-
Papenburg, 독일, 26871
- Kardiologische Gemeinschaftpraxis Papenburg
-
Pirna, 독일, 01796
- Hausärztlich-kardiologisches MVZ,,Am Felsenkeller" GmbH
-
Potsdam, 독일, 14469
- Kardiologische Gemeinschaftspraxis am Park Sanssouci
-
Regensburg, 독일, 93053
- Lipidambulanz Uniklinikum Regensburg
-
Stanhsdorf B. Berlin, 독일, 14532
- Parkkardiologie, kard. Gemeinschaftspraxis
-
Trier, 독일, 54292
- Diabetologische Schwerpunktpraxis
-
Trier, 독일, 54292
- BBT Trier
-
Ulm, 독일, 89077
- Herzklinik
-
Wuppertal, 독일, 42103
- Dialysezentrum Hofaue
-
-
-
-
-
Aalst, 벨기에, 9300
- Azorg
-
Antwerp, 벨기에, 2650
- UZA (Antwerp University Hospital)
-
Boussu, 벨기에, 7301
- Epicure Hornu
-
Brasschaat, 벨기에, 2930
- A.Z. KLINA Brasschaat
-
Bruges, 벨기에, 8400
- Algemeen Ziekenhuis Sint-Jan Oostende
-
Brussels, 벨기에, 1090
- UZ Brussel
-
Brussels, 벨기에, 1020
- CHU Brugman
-
Charleroi, 벨기에, 6042
- CHU Charleroi Hopital civil Marie-Curie
-
Charleroi, 벨기에, 6060
- GHDC Charleroi - Site Hôpital Saint-Joseph
-
Genk, 벨기에, 3600
- Z.O.L - Campus St. Jan
-
Ghent, 벨기에, 9000
- UZ Gent
-
Ghent, 벨기에, 9000
- Az Sint Lucas
-
Huy, 벨기에, 4500
- CHR Huy
-
Kortrijk, 벨기에, 8500
- AZ Groeninge Kortrijk
-
La Louvrière, 벨기에, 7100
- Pôle hospitalier Jolimont
-
Leper, 벨기에, 8900
- JAN YPERMAN Ziekenhuis
-
Leuven, 벨기에, 3000
- UZ Leuven
-
Liège, 벨기에, 4000
- CHR Citadelle de Liège
-
Mons, 벨기에, 7000
- CHU Mons Ambroise Paré
-
Roeselare, 벨기에, 8800
- AZ Delta
-
Ronse, 벨기에, 9600
- AZ Glorieux
-
Yvoir, 벨기에, 5530
- CHU UCL Mont-Godinne
-
-
-
-
-
Albacete, 스페인, 02006
- H. Univers. De Albacete
-
Alicante, 스페인, 03010
- Hospital General Universitario Dr. Balmis
-
Alicante, 스페인, 03203
- H. General de Elche
-
Alicante, 스페인, 03550
- Hospital Universitario de San Juan
-
Barakaldo, 스페인, 48903
- Hospital Universitario de Cruces
-
Burgos, 스페인, 09006
- Hospital Universitario de Burgos
-
Cadiz, 스페인, 11510
- Hospital Universitario Puerto Real
-
Cadiz, 스페인, 11009
- H. Univ. Puerta del Mar
-
Cadiz, 스페인, 11207
- H. Punta de Europa
-
Cantabria, 스페인, 39300
- Sierrallana Hospital
-
Córdoba, 스페인, 14004
- H. Univ. Reina Sofía
-
Donostia / San Sebastian, 스페인, 20014
- Hospital Universitario de Donostia
-
Gijón, 스페인, 33394
- H. Univ. De Cabueñes
-
Granada, 스페인, 18014
- H. Virgen de las Nieves
-
Huelva, 스페인, 21005
- H. Juan Ramón Jiménez
-
Jaén, 스페인, 23007
- Hospital Universitario Médico-Quirúrgico de Jaén
-
Las Palmas de GC, 스페인, 35010
- Hospital Universitario de Gran Canarias Dr. Negrín
-
León, 스페인, 24008
- Hospital de León
-
Logroño, 스페인, 26006
- Hospital San Pedro
-
Marbella (Málaga), 스페인, 29603
- H. Costa del Sol
-
Murcia, 스페인, 30003
- Hospital General Universitario Reina Sofía
-
Murcia, 스페인, 30120
- H. Virgen de la Arrixaca
-
Málaga, 스페인, 29010
- H. Virgen de la Victoria
-
Málaga, 스페인, 29400
- Hospital Serranía de Ronda
-
Oviedo, 스페인, 33011
- Hospital Universitario Central de Asturias
-
Palma de Mallorca, 스페인, 07198
- Hospital Universitario Son LLatzer
-
Pamplona, 스페인, 31008
- Hospital Universitario de Navarra
-
Pamplona, 스페인, 31008
- Clínica Universidad de Navarra
-
Santa Cruz de Tenerife, 스페인, 38320
- Hospital Universitario de Canarias
-
Segovia, 스페인, 40002
- Hospital de Segovia
-
Toledo, 스페인, 45007
- Hospital General Universitario de Toledo
-
Valencia, 스페인, 46026
- Hospital La Fe
-
Valencia, 스페인, 46010
- H. Clínico Univ. De Valencia
-
Valencia, 스페인, 46014
- Consorcio Hospital General Univ de Valencia
-
Vitoria-Gasteiz, 스페인, 01009
- Hospital Universitario de Álava
-
Zaragoza, 스페인, 50009
- Hospital Clinico Universitaro Lozano Blesa
-
-
-
-
-
Braunau am Inn, 오스트리아, 5280
- Innere Medizin
-
Feldkirch, 오스트리아, 6800
- Innere Medizin 1
-
Graz, 오스트리아, 8036
- Uniklinik Graz, Endokrinologie und Diabetes
-
Graz, 오스트리아, 8036
- Uniklinik Graz, Kardiologie
-
Innsbruck, 오스트리아, 6020
- Innere Medizin 3 - Kardiologie
-
Kepler Universitätsklinikum Gmb+, 오스트리아, 4600
- Klinikum Wels-Grieskirchen GmbH+B18
-
Klagenfurt, 오스트리아, 9020
- Innere Medizin
-
Linz, 오스트리아, 4020
- Innere Medizin
-
Linz, 오스트리아, 4021
- Kepler Universitätsklinikum GmbH Klinik für Innere Medizin 1 - Kardiologie und Internistische Intensivmedizin
-
Linz, 오스트리아, 4040
- Kardiologie-Urfahr Dr. Hönig & Dr. Gammer & Dr. Buchmayr
-
Mattersburg, 오스트리아, 7210
- Ordination
-
Mistelbach, 오스트리아, 2130
- Landesklinikum Mistelbach - Gänserndorf
-
Saint Stefan Bei Graz, 오스트리아, 8511
- Ordination Dr. med. univ. Evelyn Fließer-Görzer
-
Salzburg, 오스트리아, 5020
- Praxis Gesundheitszentrum Moos 15 (Praxis Prof. Lichtenauer)
-
Salzburg, 오스트리아, 5026
- DOZ (Dialyse- und Ordinationszentrum) Privatklinik Wehrle-Diakonissen
-
Vienna, 오스트리아, 1090
- AKH Wien
-
Vienna, 오스트리아, 1060
- Zentrum für Klinische Studien Dr. Hanusch GmbH
-
Vienna, 오스트리아, 1030
- Klinik Landstrasse, Kardiologie
-
Vienna, 오스트리아, 1060
- Ordination Univ.-Prof. Dr. Kurt Huber
-
Vienna, 오스트리아, 1090
- Meduni Wien, Endokrinologie und Diabetes
-
Vienna, 오스트리아, 1090
- Meduni Wien, Kardiologie
-
Vienna, 오스트리아, 1130
- Clinic Hietzing
-
Vienna, 오스트리아, 1180
- Herzzentrum 18
-
Vienna, 오스트리아, 1210
- Karl Landsteiner Institut für kardiovaskuläre und intensivmedizinische Forschung c/o Abteilung für Kardiologie, Klinik Floridsdorf
-
-
-
-
-
Acquaviva delle Fonti, 이탈리아, 70021
- Ente Ecclesiastico "Miulli"
-
Ancona, 이탈리아, 60127
- INRCA
-
Avellino, 이탈리아, 83100
- AO Moscati
-
Bari, 이탈리아, 70123
- Osp. "San Paolo"
-
Bolzano, 이탈리아, 39100
- Ospedale di Bolzano
-
Brescia, 이탈리아, 25123
- Spedali Civili di Brescia
-
Casale Monferrato, 이탈리아, 15033
- Osp. santo spirito
-
Caserta, 이탈리아, 81100
- Ospedale Sant'Anna e san Sebastiano
-
Catanzaro, 이탈리아, 88100
- Policlinnico Mater Domini
-
Chieti, 이탈리아, 66100
- Osp. SS Annunziata
-
Enna, 이탈리아, 94100
- PO Nuovo Umberti I
-
Ferrara, 이탈리아, 44124
- Osp. Sant'Anna di Cona
-
Foggia, 이탈리아, 71122
- Policlinico "Riuniti"
-
Genova, 이탈리아, 16132
- Policlinico San Martino
-
Grosseto, 이탈리아, 58100
- Osp della Misericordia
-
Lecce, 이탈리아, 73100
- Osp. "Vito Fazzi"
-
Legnagno, 이탈리아, 37045
- Ospedale Mater Salutis
-
Livorno, 이탈리아, 57124
- Spedali Riuniti
-
Mantua, 이탈리아, 46100
- Ospedale di Mantova
-
Messina, 이탈리아, 98124
- Policlinico G. Martino
-
Milan, 이탈리아, 20138
- IRCCS Monzino
-
Milan, 이탈리아, 20157
- IRCCS Galeazzi Sant'Ambrogio
-
Modena, 이탈리아, 41125
- Policlinico Modena
-
Naples, 이탈리아, 80131
- AO Cardarelli
-
Naples, 이탈리아, 80131
- Policlinico Federico II
-
Naples, 이탈리아, 80138
- AOU Vanvitelli, I Policlinico
-
Palermo, 이탈리아, 90127
- Policlinico P. Giaccone
-
Pavi, 이탈리아, 27100
- ICS Maugeri
-
Perugia, 이탈리아, 06129
- S. Maria della Misericordia
-
Pescara, 이탈리아, 65124
- Presidio Ospedaliero
-
Peschiera, 이탈리아, 37019
- Ospedale PederzoliItlit
-
Pisa, 이탈리아, 56124
- Cisanello
-
Ravenna, 이탈리아, 48121
- Osp. Santa Maria delle Croci
-
Rivoli, 이탈리아, 10098
- Osp infermi di rivoli
-
Roma, 이탈리아, 00133
- Policlinico Tor Vergata
-
Roma, 이탈리아, 00157
- Ospedale Pertini
-
Roma, 이탈리아, 00189
- Ospedale Sant'Andrea
-
Rome, 이탈리아, 00161
- Policlinico Umberto I
-
Torino, 이탈리아, 10128
- Ospedale Mauriziano
-
Torino, 이탈리아, 10126
- Molinette Università to
-
Trieste, 이탈리아, 34149
- Osp. di Cattinara
-
Venezia, 이탈리아, 30026
- Ospedale di Portogruaro
-
Verona, 이탈리아, 37126
- AOUI Verona
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Prospective data from routine clinical practice will be collected over the course of 1 year involving approximately 2000 patients across approximately 200 sites in Europe (Germany, Italy, Spain, Austria, and Belgium) treated by both specialized and non-specialized physicians in hospital and office-based settings.
설명
Key Inclusion Criteria:
-
Written informed consent to participate
-
At least 18 years of age
-
High and very high risk patients as assessed by the physician suffering from documented primary hypercholesterolemia or mixed dyslipidemia at start of bempedoic acid treatment
-
Patients treated with:
- bempedoic acid added to ezetimibe and rosuvastatin or atorvastatin,
- bempedoic acid plus ezetimibe added to rosuvastatin or atorvastatin,
- bempedoic acid plus atorvastatin or rosuvastatin added to ezetimibe
- initiation of bempedoic acid, ezetimibe, and atorvastatin or rosuvastatin simultaneously
6) Initiation of triple therapy within a maximum of four weeks prior to inclusion 7) An untreated LDL-C value must be available within 5 years prior to the start of the triple therapy. Untreated means that the LDL-C value is not influenced by any lipid lowering therapy at the time of blood collection. Time window for not being treated as specified in the protocol.
8) No contraindications exist according to the SmPC of bempedoic acid, the respective statin and ezetimibe as per physicians' assessment 9) No concurrent participation in an interventional study (simultaneous participation in other non-interventional studies is possible) 10) Life expectancy > 1 -year
Key Exclusion Criteria:
- Patients who have received PCSK9i monoclonal antibody treatment in the last 3 months before the start of the triple therapy exposure
- Patients who have ever received PCSK9i-siRNA treatment
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Triple therapy
Adult patients who have been diagnosed with primary hypercholesterolaemia (heterozygous familial and nonfamilial) or mixed dyslipidaemia treated with bempedoic acid in combination with ezetimibe and either rosuvastatin or atorvastatin (ie, triple therapy) and will be followed for up to 1 year after initiation of triple therapy. A direct comparison between rosuvastatin and atorvastatin is not planned, only an assessment of triple therapy on LDL-C change in patients with primary hypercholesterolaemia. |
No drug was administered in this observational study. No drug was administered in this observational study. No drug was administered in this observational study. No drug was administered in this observational study. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Relative LDL-C change between untreated and 8 week after triple therapy start
기간: Baseline to 8 weeks after initiation of triple therapy
|
LDL-C will be assessed using a standard lipid panel blood test, |
Baseline to 8 weeks after initiation of triple therapy
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Proportion of patients at ESC/EAS 2019 dyslipidemia guideline goal at 8 weeks and 1 year
기간: Baseline to 1 year after initiation of triple therapy
|
The 2019 EAS/ESC guidelines recommend treatment targets of at least a 50% reduction from baseline LDL-C levels and an LDL-C concentration below 1.8 mmol/L for patients at high and 1.4 mmol/l for patients at very high cardiovascular risk. |
Baseline to 1 year after initiation of triple therapy
|
|
Relative LDL-C change between untreated and 1 year after triple therapy start
기간: From any prior LMT exposure to 1 year after initiation of triple therapy
|
LDL-C will be assessed using a standard lipid panel blood test, |
From any prior LMT exposure to 1 year after initiation of triple therapy
|
|
Relative LDL-C change between pre-bempedoic acid/pre-FDC initiation and 8 weeks after triple therapy start
기간: From pre-bempedoic acid/pre-FDC initiation to 8 weeks after initiation of triple therapy
|
LDL-C will be assessed using a standard lipid panel blood test, |
From pre-bempedoic acid/pre-FDC initiation to 8 weeks after initiation of triple therapy
|
|
Relative LDL-C change between pre-bempedoic acid/pre-FDC initiation and 1 year after triple therapy start
기간: From pre-bempedoic acid/pre-FDC initiation to 1 year after initiation of triple therapy
|
LDL-C will be assessed using a standard lipid panel blood test, |
From pre-bempedoic acid/pre-FDC initiation to 1 year after initiation of triple therapy
|
|
Relative change in laboratory values between triple therapy start and 8 weeks and 1 year thereafter
기간: Baseline to 1 year after initiation of triple therapy
|
Labs will be assessed using a standard panel blood test, |
Baseline to 1 year after initiation of triple therapy
|
|
Patient and physician reported adherence at 8 weeks and 1 year after triple therapy start
기간: Baseline to 1 year after initiation of triple therapy
|
Adherence will be judged by the physician/patient. |
Baseline to 1 year after initiation of triple therapy
|
|
Incidence of adverse events under triple therapy exposure
기간: Baseline to 1 year after initiation of triple therapy
|
Adverse events are defined as any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. |
Baseline to 1 year after initiation of triple therapy
|
|
Proportion of patients with MACE-3 and MACE-4 events
기간: Baseline to 1 year after initiation of triple therapy
|
MACE-3 and MACE-4 events will consist of non-fatal MI, non-fatal stroke, CV-death, and coronary revascularization (for MACE-4 only). |
Baseline to 1 year after initiation of triple therapy
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- DSE-BMP-01-24-EU
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .